Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07665788 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Inhaled Amikacin Versus Placebo in Patients With Ventilator-associated Tracheobronchitis

Name: Inhaled Amikacin Versus Placebo in Patients With Ventilator-associated Tracheobronchitis — clinical trial record (NCT07665788)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: AMIVAT

StatusNot Yet Recruiting

PhasePhase 3

SponsorUniversity Hospital, Tours

Started2026-06-01

View on ClinicalTrials.gov ↗

University Hospital, Tours

120 trials monitored

See 2 trials at risk

The primary objective of the AMIVAT trial is to assess whether a 5-day course of inhaled amikacin, compared to placebo, reduces the incidence of progression to ventilator-associated pneumonia (VAP) at day 28 in intensive care unit (ICU) patients with ventilator-associated tracheobronchitis (VAT). Transition from VAT to VAP will be defined as the occurrence of a first VAP episode due to the same pathogens than those responsible for VAT.

Trial Details

NCT Number	NCT07665788
Lead Sponsor	University Hospital, Tours Collaborators: Aerogen
Conditions	Ventilator-Associated Pneumonia, Ventilator-Associated Tracheobronchitis
Enrollment	250 participants
Start Date	2026-06-01
Primary Completion	2029-07-01 (estimated)
Study Completion	2029-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-24